Mediwound Ltd (MDWD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $185.63M
Last updated: Nov 17, 2026 at 11:04 AM ET
Mediwound Ltd (MDWD) Earnings: Report Dates and Results
Mediwound (MDWD) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Mediwound reported EPS of -$0.65, above the -$0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MDWD has an expected report date of Mar 3, 2027.
MDWD Earnings Call
The latest MDWD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, MDWD beat 22, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.57M, down 34.3% from $5.43M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.65 | -$0.66 | -$0.92 - -$0.62 | +1.52% | Beat | N/A | 5 | 2 up, 3 down | Nov 12, 2026 | $3.57M |
| Jun 30, 2026 | -$0.77 | -$0.76 | -$0.91 - -$0.68 | -1.32% | Miss | N/A | 5 | 1 up, 2 down | Aug 13, 2026 | $3.09M |
| Mar 31, 2026 | -$0.23 | -$0.66 | -$0.73 - -$0.62 | +65.15% | Beat | N/A | 5 | 1 up, 2 down | May 27, 2026 | $1.48M |
| Dec 31, 2025 | -$0.56 | -$0.61 | -$0.77 - -$0.39 | +8.20% | Beat | N/A | 5 | 0 up, 3 down | Mar 5, 2026 | $1.87M |
| Sep 30, 2025 | -$0.24 | -$0.83 | -$1.38 - -$0.60 | +71.08% | Beat | N/A | 5 | 1 up, 3 down | Nov 20, 2025 | $5.43M |
| Jun 30, 2025 | -$1.23 | -$0.57 | -$0.70 - -$0.30 | -115.79% | Miss | N/A | 5 | 3 up, 1 down | Aug 14, 2025 | $5.71M |
| Mar 31, 2025 | -$0.07 | -$0.66 | -$0.73 - -$0.61 | +89.39% | Beat | N/A | 5 | N/A | May 21, 2025 | $3.96M |
| Dec 31, 2024 | -$0.36 | -$0.59 | -$0.74 - -$0.52 | +38.98% | Beat | N/A | 4 | 1 up, 2 down | Mar 19, 2025 | $5.84M |
| Sep 30, 2024 | -$0.98 | -$0.44 | -$0.49 - -$0.38 | -122.73% | Miss | N/A | 3 | 2 up, 0 down | Nov 26, 2024 | $4.36M |
| Jun 30, 2024 | -$0.68 | -$0.42 | -$0.48 - -$0.39 | -61.90% | Miss | -780.0% | 4 | 1 up, 0 down | Aug 14, 2024 | $5.06M |
| Mar 31, 2024 | -$1.05 | -$0.41 | -$0.44 - -$0.35 | -156.10% | Miss | N/A | 3 | 0 up, 0 down | May 29, 2024 | $4.96M |
| Dec 31, 2023 | -$0.19 | -$0.23 | -$0.40 - $0.07 | +17.39% | Beat | N/A | 4 | 0 up, 0 down | Mar 21, 2024 | $5.34M |
| Sep 30, 2023 | -$0.24 | -$0.39 | -$0.57 - -$0.36 | +38.46% | Beat | N/A | 4 | 0 up, 0 down | Nov 21, 2023 | $4.78M |
| Jun 30, 2023 | $0.10 | -$0.34 | -$0.52 - -$0.26 | +129.41% | Beat | N/A | 3 | 0 up, 0 down | Aug 15, 2023 | $4.77M |
| Mar 31, 2023 | -$0.44 | -$0.43 | -$0.68 - $0.32 | -2.33% | Miss | N/A | 4 | 1 up, 0 down | May 30, 2023 | $3.80M |
| Dec 31, 2022 | -$1.18 | -$0.59 | -$0.70 - -$0.38 | -100.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 16, 2023 | $11.62M |
| Sep 30, 2022 | -$0.91 | -$0.68 | -$0.77 - -$0.56 | -33.82% | Miss | N/A | 4 | 0 up, 0 down | Nov 15, 2022 | $5.80M |
| Jun 30, 2022 | -$0.91 | -$0.68 | -$0.84 - -$0.56 | -33.82% | Miss | N/A | 6 | 0 up, 0 down | Aug 9, 2022 | $4.67M |
| Mar 31, 2022 | -$0.84 | -$0.76 | -$0.98 - -$0.42 | -10.53% | Miss | N/A | 5 | 0 up, 0 down | May 17, 2022 | $4.41M |
| Dec 31, 2021 | -$1.05 | -$1.05 | -$1.19 - -$0.91 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Mar 17, 2022 | $5.49M |
| Sep 30, 2021 | -$0.84 | -$0.90 | -$1.05 - -$0.77 | +6.67% | Beat | N/A | 6 | N/A | Nov 16, 2021 | $6.37M |
| Jun 30, 2021 | -$0.84 | -$0.78 | -$0.98 - $0.91 | -7.69% | Miss | N/A | 6 | N/A | Aug 10, 2021 | $6.06M |
| Mar 31, 2021 | -$0.70 | -$0.81 | -$1.05 - -$0.42 | +13.58% | Beat | N/A | 6 | N/A | May 5, 2021 | $5.85M |
| Dec 31, 2020 | -$0.42 | -$0.79 | -$0.98 - -$0.49 | +46.84% | Beat | N/A | 5 | N/A | Feb 25, 2021 | $6.67M |
| Sep 30, 2020 | -$0.49 | -$0.67 | -$0.91 - -$0.42 | +26.87% | Beat | N/A | 5 | N/A | Nov 10, 2020 | $6.63M |
| Jun 30, 2020 | -$0.77 | -$0.84 | -$0.98 - -$0.70 | +8.33% | Beat | -123.4% | 4 | N/A | Aug 6, 2020 | $4.03M |
| Mar 31, 2020 | -$0.63 | -$1.00 | -$1.19 - -$0.91 | +37.00% | Beat | N/A | 4 | N/A | May 20, 2020 | $4.44M |
| Dec 31, 2019 | -$0.91 | -$0.73 | -$1.19 - -$0.21 | -24.66% | Miss | N/A | 5 | N/A | Feb 25, 2020 | $5.44M |
| Sep 30, 2019 | -$0.77 | -$0.91 | -$1.33 - -$0.77 | +15.38% | Beat | N/A | 5 | N/A | Nov 14, 2019 | $5.14M |
| Jun 30, 2019 | $3.29 | -$0.18 | -$1.19 - $3.36 | N/A | N/A | N/A | 5 | N/A | Aug 13, 2019 | $20.75M |
| Mar 31, 2019 | -$1.05 | -$0.98 | -$1.05 - -$0.84 | -7.14% | Miss | N/A | 4 | N/A | May 21, 2019 | $461000 |
| Dec 31, 2018 | -$0.35 | -$1.06 | -$1.33 - -$0.91 | +66.98% | Beat | N/A | 5 | N/A | Mar 25, 2019 | $992000 |
| Sep 30, 2018 | -$0.77 | -$1.37 | N/A | +43.80% | Beat | N/A | N/A | N/A | Nov 13, 2018 | $858000 |
| Jun 30, 2018 | -$1.05 | -$1.37 | -$2.03 - -$0.91 | +23.36% | Beat | N/A | 5 | N/A | Aug 7, 2018 | $1.03M |
| Mar 31, 2018 | -$1.19 | -$0.94 | -$1.75 - -$0.84 | -26.60% | Miss | N/A | 5 | N/A | May 10, 2018 | $520000 |
| Dec 31, 2017 | -$0.63 | -$1.19 | -$1.47 - -$0.98 | +47.06% | Beat | N/A | 5 | N/A | Mar 19, 2018 | $530000 |
| Sep 30, 2017 | -$1.12 | -$1.33 | -$1.40 - -$1.19 | +15.79% | Beat | N/A | 5 | N/A | Nov 16, 2017 | $739000 |
| Jun 30, 2017 | -$1.40 | -$1.37 | -$1.61 - -$0.91 | -2.19% | Miss | N/A | 5 | N/A | Aug 3, 2017 | $687000 |
| Mar 31, 2017 | -$1.40 | -$1.18 | N/A | -18.64% | Miss | N/A | N/A | N/A | May 8, 2017 | $540000 |
| Dec 31, 2016 | -$0.63 | -$1.74 | N/A | +63.79% | Beat | N/A | N/A | N/A | Feb 21, 2017 | $430000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.10, after -$3.07 the year before. It was -$6.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.10 | N/A |
| Dec 31, 2024 | -$3.07 | N/A |
| Dec 31, 2023 | -$0.77 | N/A |
| Dec 31, 2022 | -$3.84 | N/A |
| Dec 31, 2021 | -$3.43 | N/A |
| Dec 31, 2020 | -$2.31 | -512.5% |
| Dec 31, 2019 | $0.56 | N/A |
| Dec 31, 2018 | -$3.36 | N/A |
| Dec 31, 2017 | -$4.55 | N/A |
| Dec 31, 2016 | -$6.02 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,021 | 9 | |
| 2026Q2 | Jun 30, 2026 | 5,247 | 11 | |
| 2026Q1 | Mar 31, 2026 | 4,627 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,239 | 11 | |
| 2025Q3 | Sep 30, 2025 | 4,009 | 9 | |
| 2025Q2 | Jun 30, 2025 | 4,585 | 10 | |
| 2025Q1 | Mar 31, 2025 | 4,152 | 9 |
2026Q3 Earnings Call
Opening remarks
Gaia Vasiliver-Shamis Lifesci Advisors Representative Thank you, Sagar, and welcome, everyone. Earlier today, before the market opened, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2026. You may access this press release on the company's website under the Investors tab. I would ask you to review the full text of our forward-looking statements within this morning's press release. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC. In addition, all forward-looking statements represent our view only as of today, and MediWound assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise. This conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A. Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?
Ofer Gonen CEO Thank you, Gaia, and good morning, everyone. During the third quarter, we advanced EscharEx development, supported NexoBrid's commercial growth and government program, and continued preparing our expanded manufacturing facility to meet future demand. Let me start with an update on EscharEx. The global Phase III VALUE trial in venous leg ulcers remains our top priority. Enrollment continues, and we remain on track to complete the prespecified interim sample size reassessment and enrollment by the end of the first quarter of 2027. The current enrollment target is 216 patients across approximately 40 sites in the United States, Europe, and Israel. During the quarter, the Independent Data and Safety Monitoring Board completed its prespecified periodic review of the VALUE trial, identified no safety concerns, and recommended that the trial continue as planned without modifications. The next DSMB meeting is scheduled for early January 2027. The following meeting is expected at the end of the first quarter of 2027, at which the DSMB will also conduct the interim sample size reassessment. Beyond venous leg ulcers, we continue to advance toward clinical trials in diabetic foot ulcers and pressure ulcers.
Frequently Asked Questions About MDWD
When is Mediwound's next earnings date?
Mediwound's next earnings report is expected for Mar 3, 2027.
Did MDWD beat earnings estimates last quarter?
Yes. Mediwound reported EPS of -$0.65 for the quarter ended Sep 30, 2026, above the -$0.66 estimate, a 1.52% surprise.
What EPS do analysts expect from MDWD next quarter?
The consensus EPS estimate for Mediwound for the quarter ending Dec 31, 2026 is -$0.65 from 8 analysts, with estimates from -$0.77 to -$0.55.
How often does MDWD beat earnings estimates?
Mediwound beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +19.65%.
MDWD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts